WO2006136284A1 - Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder - Google Patents

Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder Download PDF

Info

Publication number
WO2006136284A1
WO2006136284A1 PCT/EP2006/005390 EP2006005390W WO2006136284A1 WO 2006136284 A1 WO2006136284 A1 WO 2006136284A1 EP 2006005390 W EP2006005390 W EP 2006005390W WO 2006136284 A1 WO2006136284 A1 WO 2006136284A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pharmaceutical composition
formula
group
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/005390
Other languages
French (fr)
Inventor
Beatrice Garrone
Maurizio Magnani
Guido Furlotti
Nicola Cazzolla
Angelo Guglielmotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2006800148322A priority Critical patent/CN101171011B/en
Priority to CA2604584A priority patent/CA2604584C/en
Priority to US11/910,559 priority patent/US7879836B2/en
Priority to EP06754160A priority patent/EP1893208B1/en
Priority to DE602006006827T priority patent/DE602006006827D1/en
Priority to BRPI0611719-8A priority patent/BRPI0611719A2/en
Priority to EA200800125A priority patent/EA012443B1/en
Priority to DK06754160T priority patent/DK1893208T3/en
Priority to PL06754160T priority patent/PL1893208T3/en
Priority to AU2006261296A priority patent/AU2006261296B9/en
Priority to JP2008517359A priority patent/JP5142991B2/en
Priority to MX2007014396A priority patent/MX2007014396A/en
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority to HK08104469.6A priority patent/HK1111080B/en
Priority to KR1020077030116A priority patent/KR101324689B1/en
Priority to AT06754160T priority patent/ATE431146T1/en
Publication of WO2006136284A1 publication Critical patent/WO2006136284A1/en
Priority to IL186334A priority patent/IL186334A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to the pharmaceutical use of a 1-(3- chlorophenyl)-3-alkylpiperazine having a chiral centre (S) and of 5 pharmaceutically acceptable acid addition salts thereof.
  • the present invention relates to the use of a 1-(3- chlorophenyl)-3-alkylpiperazine having a chiral centre (S) and of pharmaceutically acceptable acid addition salts thereof in the treatment of appetite disorders.
  • Patent US 3 253 989 describes an N-phenylpiperazine of formula
  • R is H, m-CI, p-CI, m-CH3 or p-CH3, endowed with anorexigenic activity.
  • N-phenylpiperazines endowed with hypophagia- 20 inducing activity are described in the literature, for example m- trifluoromethyl phenylpiperazine (TFMPP) (Eur J Pharmacol, 1987; 141 : 429).
  • TFMPP m- trifluoromethyl phenylpiperazine
  • N-phenylpiperazines are limited by CNS side- effects which cause changes in mood and behaviour leading to 25 induction of anxiety states which often result in panic attacks.
  • Obesity is defined in terms of BMI (Body Mass Index) calculated as weight (kg)/[height (m)] 2 .
  • BMI Body Mass Index
  • a BMI below 25 is considered normal, from 25 to 29.9 is considered overweight, whereas a BMI above 30 is an indicator of obesity.
  • One of the commonest causes of an overweight condition and of obesity is an excessive calorie intake which is not utilized by the body, but is accumulated in the adipose tissue.
  • WO 93/14091 describes a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I):
  • R is an alkyl group having from 1 to 3 carbon atoms, as an intermediate for preparing alkyl derivatives of trazodone.
  • a first aspect of the present invention therefore relates to the pharmaceutical use of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I), in racemic (R 1 S) form or in the form of the (S) enantiomer,
  • R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid.
  • this pharmaceutical use comprises the treatment of an appetite disorder.
  • said appetite disorder is selected from the group comprising hyperphagia, bulimia and obesity.
  • a second aspect of the present invention relates to a pharmaceutical composition that includes a therapeutically effective amount of a 1-(3- chlorophenyl)-3-alkylpiperazine of formula (I), in (R 1 S) racemic form or in the form of (S) enantiomer,
  • R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, and at least one pharmaceutically acceptable excipient.
  • R is methyl or ethyl. Even more preferably, R is methyl.
  • the compound of formula (I) is an enantiomer of (S) configuration.
  • said organic acid is selected from the group comprising maleic, methanesulphonic, paratoluenesulphonic, succinic and citric acid.
  • said inorganic acid is typically selected from the group comprising hydrochloric, hydrobromic, phosphoric and sulphuric acid.
  • the preferred acid is hydrochloric acid.
  • optically active acids such as lactic acid and tartaric acid, both in the natural L(+) form.
  • the preferred acid is L(+) tartaric acid.
  • the compound of formula (I) in racemic (R 1 S) form can be prepared by known techniques, for example reaction scheme 3 described in WO 93/14091.
  • the enantiomer in the (S) configuration can also be obtained by known techniques, for example those described by M. Giannangeli et al. (loc. cit.).
  • the anxiogenic activity of the compounds of the present invention was investigated by means of the social interaction test in the rat, which, as is known by a person skilled in the art, represents an experimental model that is predictive of the effects in humans.
  • the normal social interaction of rats is generally suppressed when the animals are put in an unfamiliar environment.
  • Measurement of the time spent by pairs of animals in interacting with one another and exploring their surroundings constitutes a model for verifying the action of substances that influence social behaviour.
  • the social interaction test shows numerous similarities between the behaviour exhibited by the rats and anxiety states in humans and proves to be a useful tool for demonstrating effects on mood, both of the anxiogenic and of the anxiolytic type.
  • hypophagia-inducing activity of the compounds of formula (I) was demonstrated by verifying the food consumption of food-deprived rats.
  • Verification of the consumption of food in food-deprived rats represents a condition that reproduces the complex system regulating the sensation of hunger and the intake of food in humans. Fasting in fact introduces many physiological changes that can lead to activation of the circuits that are specifically dedicated to the control of food intake. As is well known, the use of this model constitutes a valid tool for identifying substances capable of interfering with appetite disorders and can be used in particular for monitoring conditions such as hyperphagia, bulimia and obesity.
  • compositions of the present invention are prepared as suitable dosage forms containing an effective dose of at least one compound of formula (I) or of a pharmaceutically acceptable salt thereof with an organic or inorganic acid and at least one pharmaceutically acceptable inert ingredient.
  • suitable dosage forms are tablets, capsules, coated tablets, granules, solutions and syrups for oral administration; medicated patches for transdermal administration; suppositories for rectal administration, and injectable sterile solutions.
  • Other suitable dosage forms are those with extended release and those based on liposomes, for administration by the oral, injectable or transdermal route.
  • the dosage forms can also contain other conventional ingredients such as: preservatives, stabilizers, surfactants, buffers, salts for regulating osmotic pressure, emulsifiers, sweeteners, colorants, flavourings and the like.
  • the pharmaceutical composition of the present invention can contain other pharmacologically active ingredients, whose concomitant administration is useful.
  • the amount of compound of formula (I) or of a pharmaceutically acceptable acid addition salt thereof in the pharmaceutical composition of the present invention can vary over a wide range depending on known factors, for example the type of pathology, the severity of the disease, the patient's body weight, the dosage form, the chosen route of administration, the number of daily doses and the efficacy of the chosen compound of formula (I). However, determination of the optimum amount is a simple and routine matter for a person skilled in the art.
  • the amount of compound of formula (I) or of a pharmaceutically acceptable acid addition salt thereof in the pharmaceutical composition of the present invention will be such as to ensure a level of administration between 0.001 and 100 mg/kg/day.
  • the level of administration is between 0.05 and 50 mg/kg/day, and even more preferably between 0.1 and 10 mg/kg/day.
  • the dosage forms of the pharmaceutical composition of the present invention can be prepared by techniques that are well known to a pharmaceutical chemist, and include mixing, granulation, compression, dissolution, sterilization and the like.
  • the compounds of the present invention can be prepared by methods that are known to a person skilled in the art.
  • the racemic compound 1 was prepared by the method described in Example 4 of WO 93/14091 whereas the two enantiomers 2 and 3 were separated with (+) and (-)-tartaric acid respectively, as described by M. Giannangeli et al. (loc. cit.).
  • the aforesaid methods can also be used for preparing the compounds of the present invention in which R is ethyl or propyl.
  • the animals were kept in a room with a controlled cycle of light and darkness (6:00-18:00). To promote acclimatization and eliminate responses induced by stress conditions, the rats were handled and were injected daily with the vehicle (water) for the four days preceding administration of the test compounds.
  • the animals were kept in a room with a controlled cycle of light and darkness (6:00-18:00). Before the test, which was carried out at 9:30 corresponding to daytime, the animals were deprived of food for 24 h. At the end of the fasting period, the animals were treated orally with the test compounds (10 mg/kg) in an aqueous vehicle and, immediately after treatment, a pre-weighed amount of food was made available. One hour after treatment, the food consumption was evaluated by weighing the amount of food remaining. The control animals were treated orally with the vehicle (water) used for administering the test compounds.
  • Fig. 2A shows that the amount of food consumed by the animals treated with the racemic compound (compound 1) of the invention is approx. 28% lower than that consumed by the control animals.
  • Fig. 2B shows that the amounts of food consumed by the animals treated with the (S) enantiomer (compound 2) and with the (R) enantiomer of the invention are approx. 75-80% and 20% lower, respectively, than that consumed by the control animals.
  • Fig. 2B therefore shows that the hypophagia-inducing activity of the racemic compound of the invention can be attributed almost entirely to the (S) enantiomer.
  • a tablet containing a compound of the present invention as active principle has the following composition:
  • a vial contains 5 ml of an injectable solution containing a compound of the present invention as active principle.
  • Said solution has the following composition: Active principle 25 mg
  • a sachet contains 5.23 g of water-dispersible granules containing a compound of the present invention as active principle. Said granules have the following composition: Active principle 50 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Use of a 1- (3-chlorophenyl) -3-alkylpiperazine of formula (I), in racemic (R, S) form or in the form of the (S) enantiomer, in which R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, for treating apetite disorder. A pharmaceutical composition that comprises a therapeutically effective amount of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I) as previously defined or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, and at least one pharmaceutically acceptable excipient.

Description

PHARMACEUTICAL COMPOSITION COMPRISING A 1-(3-CHLOROPHENYL)-S-ALKYLPIPERAZINE FOR TREATING APETITE DISORDER
***********
The present invention relates to the pharmaceutical use of a 1-(3- chlorophenyl)-3-alkylpiperazine having a chiral centre (S) and of 5 pharmaceutically acceptable acid addition salts thereof.
More particularly, the present invention relates to the use of a 1-(3- chlorophenyl)-3-alkylpiperazine having a chiral centre (S) and of pharmaceutically acceptable acid addition salts thereof in the treatment of appetite disorders.
10 Throughout the present description and the claims, the expression "having a chiral centre (S)", where used, is intended to refer both to the racemic product (R1S) and to the single (S) enantiomer.
Patent US 3 253 989 describes an N-phenylpiperazine of formula
Figure imgf000002_0001
in which R is H, m-CI, p-CI, m-CH3 or p-CH3, endowed with anorexigenic activity.
Furthermore, other N-phenylpiperazines endowed with hypophagia- 20 inducing activity are described in the literature, for example m- trifluoromethyl phenylpiperazine (TFMPP) (Eur J Pharmacol, 1987; 141 : 429).
However, use of the N-phenylpiperazines is limited by CNS side- effects which cause changes in mood and behaviour leading to 25 induction of anxiety states which often result in panic attacks.
Experimental studies have clearly demonstrated anxiogenic effects of compounds such as m-chlorophenyl-piperazine (mCPP) and TFMPP which reduce social interaction time in the rat (Eur J Pharmacol, 1989; 164: 445-54). Moreover, it has been demonstrated that mCPP induces and/or aggravates panic attacks in patients with anxiety, obsessions in patients with obsessive-compulsive disorder, states of euphoria in alcoholics and cocaine addicts and the symptomatology of schizophrenic patients (Pharmacol Rev, 1991 ; 43: 527; Biol Psychiatr, 1991 ; 30: 1139; Arch Gen Psychiatr, 1993; 50: 624; Arch Gen Psychiatr, 1993; 50: 1001 ; Arch Gen Psychiatr, 1994; 51 : 898).
These severe side-effects of the phenylpiperazines represent a serious drawback in chronic pathologies that are very important from the social standpoint, for example obesity. In fact, obesity can be regarded as a chronic pathological condition, resulting from complex interactions of cultural, psychological and genetic factors.
Obesity is defined in terms of BMI (Body Mass Index) calculated as weight (kg)/[height (m)]2. Currently, a BMI below 25 is considered normal, from 25 to 29.9 is considered overweight, whereas a BMI above 30 is an indicator of obesity.
One of the commonest causes of an overweight condition and of obesity is an excessive calorie intake which is not utilized by the body, but is accumulated in the adipose tissue.
Once the mass of adipose tissue has accumulated, its reduction is impeded by a complex series of superimposed neuroendocrine systems. This counter-regulatory mechanism, which probably develops as protection against food deprivation and against fetal or neonatal weight loss, causes changes in appetite and in metabolism which makes deliberate weight loss difficult to achieve. Over recent decades, the prevalence of obesity has increased exponentially, reaching epidemic proportions in Europe and the USA. Recent estimates suggest that, despite the continuing efforts of the public health services, the health problems of overweight and obese subjects are continuing to increase. It has been calculated that the number of obese adults in the 7 major markets (USA, France, Germany, Italy, Spain, Great Britain and Japan) is destined to increase from 95 million in 2000 to 139 million in 2010. Fewer than 25% of potential patients are diagnosed as obese and fewer than 20% of them are treated with drug therapy. This low percentage of patients receiving drug therapy is due to the limited efficacy of the available drug therapies. Thus, the drugs currently available only succeed in producing a 5-10% initial weight loss in less than 50% of patients treated.
Consequently, the need for an effective drug therapy has increased considerably in the last 30 years, also on account of the social costs associated with obesity. In fact, numerous studies have shown that being overweight greatly increases the risk of morbidity caused by various conditions including diabetes, hypertension, dyslipidaemia, coronary cardiopathies, congestive heart failure and myocardial infarction. Moreover, increased body weight is also often associated with a general increase in mortality.
WO 93/14091 describes a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I):
Figure imgf000004_0001
(I)
where R is an alkyl group having from 1 to 3 carbon atoms, as an intermediate for preparing alkyl derivatives of trazodone.
M. Giannageli et al. "Effect of Modifications of the Alkylpiperazine Moiety of Trazodone on 5-HT2A and αi Receptor Binding Affinity" Journal of Medicinal Chemistry 1999, Vol. 42: 336-345, describe a method of separating the two S and R enantiomers of the compound of formula (I) in which R is methyl with (+) and (-)-tartaric acid respectively. Furthermore, those authors also describe the stereospecific synthesis of the (S) enantiomer of the compound of formula (I) in which R is methyl.
To date, however, no therapeutic activity of the compounds of formula (I) had ever been described.
It has now been found that the 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I) having an (S) chiral centre, both as racemic (R1S) and as single (S) enantiomer, is active in the treatment of appetite disorders and is surprisingly without anxiogenic side-effects.
Moreover, even more surprisingly, it has been found that it is mainly the enantiomer of (S) configuration that possesses these properties.
A first aspect of the present invention therefore relates to the pharmaceutical use of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I), in racemic (R1S) form or in the form of the (S) enantiomer,
Figure imgf000005_0001
(O
in which
R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid.
Preferably, this pharmaceutical use comprises the treatment of an appetite disorder. Typically, said appetite disorder is selected from the group comprising hyperphagia, bulimia and obesity.
A second aspect of the present invention relates to a pharmaceutical composition that includes a therapeutically effective amount of a 1-(3- chlorophenyl)-3-alkylpiperazine of formula (I), in (R1S) racemic form or in the form of (S) enantiomer,
Figure imgf000006_0001
(I)
in which
R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, and at least one pharmaceutically acceptable excipient. Preferably R is methyl or ethyl. Even more preferably, R is methyl.
Advantageously, the compound of formula (I) is an enantiomer of (S) configuration.
Typically, said organic acid is selected from the group comprising maleic, methanesulphonic, paratoluenesulphonic, succinic and citric acid.
In its turn, said inorganic acid is typically selected from the group comprising hydrochloric, hydrobromic, phosphoric and sulphuric acid. The preferred acid is hydrochloric acid.
In the case of the compound of formula (I) in the (S) configuration, it is also possible to use optically active acids such as lactic acid and tartaric acid, both in the natural L(+) form. In that case, the preferred acid is L(+) tartaric acid.
The compound of formula (I) in racemic (R1S) form can be prepared by known techniques, for example reaction scheme 3 described in WO 93/14091.
The enantiomer in the (S) configuration can also be obtained by known techniques, for example those described by M. Giannangeli et al. (loc. cit.).
The anxiogenic activity of the compounds of the present invention was investigated by means of the social interaction test in the rat, which, as is known by a person skilled in the art, represents an experimental model that is predictive of the effects in humans.
The normal social interaction of rats (sniffing, nipping, grooming) is generally suppressed when the animals are put in an unfamiliar environment. Measurement of the time spent by pairs of animals in interacting with one another and exploring their surroundings (usually an arena consisting of a Perspex container) constitutes a model for verifying the action of substances that influence social behaviour. As is well known, the social interaction test shows numerous similarities between the behaviour exhibited by the rats and anxiety states in humans and proves to be a useful tool for demonstrating effects on mood, both of the anxiogenic and of the anxiolytic type.
The hypophagia-inducing activity of the compounds of formula (I) was demonstrated by verifying the food consumption of food-deprived rats.
As is known to a person skilled in the art, the aforesaid experimental model can also be regarded as predictive of the activity in humans.
Verification of the consumption of food in food-deprived rats represents a condition that reproduces the complex system regulating the sensation of hunger and the intake of food in humans. Fasting in fact introduces many physiological changes that can lead to activation of the circuits that are specifically dedicated to the control of food intake. As is well known, the use of this model constitutes a valid tool for identifying substances capable of interfering with appetite disorders and can be used in particular for monitoring conditions such as hyperphagia, bulimia and obesity.
Preferably the pharmaceutical compositions of the present invention are prepared as suitable dosage forms containing an effective dose of at least one compound of formula (I) or of a pharmaceutically acceptable salt thereof with an organic or inorganic acid and at least one pharmaceutically acceptable inert ingredient.
Examples of suitable dosage forms are tablets, capsules, coated tablets, granules, solutions and syrups for oral administration; medicated patches for transdermal administration; suppositories for rectal administration, and injectable sterile solutions. Other suitable dosage forms are those with extended release and those based on liposomes, for administration by the oral, injectable or transdermal route.
The dosage forms can also contain other conventional ingredients such as: preservatives, stabilizers, surfactants, buffers, salts for regulating osmotic pressure, emulsifiers, sweeteners, colorants, flavourings and the like.
If required for particular therapeutic requirements, the pharmaceutical composition of the present invention can contain other pharmacologically active ingredients, whose concomitant administration is useful.
The amount of compound of formula (I) or of a pharmaceutically acceptable acid addition salt thereof in the pharmaceutical composition of the present invention can vary over a wide range depending on known factors, for example the type of pathology, the severity of the disease, the patient's body weight, the dosage form, the chosen route of administration, the number of daily doses and the efficacy of the chosen compound of formula (I). However, determination of the optimum amount is a simple and routine matter for a person skilled in the art.
Typically, the amount of compound of formula (I) or of a pharmaceutically acceptable acid addition salt thereof in the pharmaceutical composition of the present invention will be such as to ensure a level of administration between 0.001 and 100 mg/kg/day. Preferably the level of administration is between 0.05 and 50 mg/kg/day, and even more preferably between 0.1 and 10 mg/kg/day. The dosage forms of the pharmaceutical composition of the present invention can be prepared by techniques that are well known to a pharmaceutical chemist, and include mixing, granulation, compression, dissolution, sterilization and the like.
Experimental section 1. Preparation
The compounds of the present invention can be prepared by methods that are known to a person skilled in the art.
Referring to Table 1 below, the racemic compound 1 was prepared by the method described in Example 4 of WO 93/14091 whereas the two enantiomers 2 and 3 were separated with (+) and (-)-tartaric acid respectively, as described by M. Giannangeli et al. (loc. cit.). The aforesaid methods can also be used for preparing the compounds of the present invention in which R is ethyl or propyl. The m-chlorophenyl-piperazine (mCPP), used as comparison compound, was prepared by the method described in US 3 253 989. Table 1
Figure imgf000010_0001
2. Anxiogenic activity in the rat (test of social interaction)
Male CD rats weighing 150-250 g were used.
The animals were kept in a room with a controlled cycle of light and darkness (6:00-18:00). To promote acclimatization and eliminate responses induced by stress conditions, the rats were handled and were injected daily with the vehicle (water) for the four days preceding administration of the test compounds.
On the fifth day the animals were treated intraperitoneal^ with the test compounds and, after 20 minutes, the interaction time (seconds) spent by the animals during a 10-minute period was evaluated.
The results are presented in Fig. 1 and show that the interaction time of the animals treated with the compound of the invention is approx. 90- 95% of that of the control animals (injected with water only or not treated) whereas the interaction time of the animals treated with the comparison compound (mCPP) is approx. 50% of that of the control animals.
This test therefore demonstrates that the compounds of the present invention are almost devoid of anxiogenic activity. Similar results can be obtained with the compounds of the invention in which R is ethyl or propyl. 3. Hypophagia-inducing activity in food-deprived rats
Male CD rats weighing 300-350 g were used.
The animals were kept in a room with a controlled cycle of light and darkness (6:00-18:00). Before the test, which was carried out at 9:30 corresponding to daytime, the animals were deprived of food for 24 h. At the end of the fasting period, the animals were treated orally with the test compounds (10 mg/kg) in an aqueous vehicle and, immediately after treatment, a pre-weighed amount of food was made available. One hour after treatment, the food consumption was evaluated by weighing the amount of food remaining. The control animals were treated orally with the vehicle (water) used for administering the test compounds.
The results are shown in Figs. 2A and 2B.
Fig. 2A shows that the amount of food consumed by the animals treated with the racemic compound (compound 1) of the invention is approx. 28% lower than that consumed by the control animals.
In its turn, Fig. 2B shows that the amounts of food consumed by the animals treated with the (S) enantiomer (compound 2) and with the (R) enantiomer of the invention are approx. 75-80% and 20% lower, respectively, than that consumed by the control animals.
Fig. 2B therefore shows that the hypophagia-inducing activity of the racemic compound of the invention can be attributed almost entirely to the (S) enantiomer.
Similar results can be obtained with the compounds of the invention in which R is ethyl or propyl. 4. Pharmaceutical Compositions 4.1 Tablet
A tablet containing a compound of the present invention as active principle has the following composition:
Active principle 50 mg
Lactose monohydrate 161 mg
Dibasic calcium phosphate dihydrate 161 mg
Microcrystalline cellulose 95 mg
Maize starch 30 mg
Sodium carboxymethylamide 24 mg
Povidone 11 mg
Magnesium stearate 3 mg 4.2 Injectable solution
A vial contains 5 ml of an injectable solution containing a compound of the present invention as active principle.
Said solution has the following composition: Active principle 25 mg
Sorbitol q.s.f. isoosmotic solutions
Sterile water for injection q.s.f. 5 ml
4.3 Granules A sachet contains 5.23 g of water-dispersible granules containing a compound of the present invention as active principle. Said granules have the following composition: Active principle 50 mg
Maltitol 1300 mg
Mannitol 2700 mg
Sucrose 1000 mg
Citric acid 15 mg
Aspartame 15 mg
Flavourings 150 mg

Claims

1. Pharmaceutical use of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I), in racemic (R1S) form or in the form of the (S) enantiomer,
Figure imgf000013_0001
(I)
in which
R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid.
2. Use according to Claim 1 , characterized in that said pharmaceutical use comprises the treatment of an appetite disorder.
3. Use according to Claim 2, characterized in that said appetite disorder is selected from the group comprising hyperphagia, bulimia and obesity.
4. Use according to any one of the preceding claims, characterized in that R is methyl or ethyl.
5. Use according to any one of the Claims from 1 to 3, characterized in that R is methyl.
6. Use according to any one of the preceding claims, characterized in that the compound of formula (I) is an enantiomer of (S) configuration.
7. Use according to any one of the preceding claims, characterized in that said organic acid is selected from the group comprising maleic, methanesulphonic, paratoluenesulphonic, succinic and citric acid.
8. Use according to any one of the Claims from 1 to 6, characterized in that said inorganic acid is selected from the group comprising hydrochloric, hydrobromic, phosphoric and sulphuric acid.
9. Use according to any one of the Claims from 1 to 6, characterized in that said acid is hydrochloric acid.
10. Use according to Claim 6, characterized in that said acid is selected from the group comprising L(+) lactic and L(+) tartaric acid.
11. Pharmaceutical composition containing a therapeutically effective amount of a 1-(3-chlorophenyl)-3-alkylpiperazine of formula (I), in racemic (R1S) form or in the form of (S) enantiomer,
Figure imgf000014_0001
(I)
in which
R is a linear or branched alkyl group having from 1 to 3 carbon atoms, or of an addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, and at least one pharmaceutically acceptable excipient.
12. Pharmaceutical composition according to Claim 11 , characterized in that R is methyl or ethyl.
13. Pharmaceutical composition according to Claim 11 , characterized in that R is methyl.
14. Pharmaceutical composition according to any one of the preceding claims, characterized in that the compound of formula (I) is an enantiomer of (S) configuration.
15. Pharmaceutical composition according to any one of the preceding claims, characterized in that said organic acid is selected from the group comprising maleic, methanesulphonic, paratoluenesulphonic, succinic and citric acid.
16. Pharmaceutical composition according to any one of the Claims from 11 to 14, characterized in that said inorganic acid is selected from the group comprising hydrochloric, hydrobromic, phosphoric and sulphuric acid.
17. Pharmaceutical composition according to any one of the Claims from 11 to 14, characterized in that said acid is hydrochloric acid.
18. Pharmaceutical composition according to Claim 14, characterized in that said acid is selected from the group comprising L(+) lactic and
L(+) tartaric acid.
PCT/EP2006/005390 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder Ceased WO2006136284A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CA2604584A CA2604584C (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
US11/910,559 US7879836B2 (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating appetite disorder
EP06754160A EP1893208B1 (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
DE602006006827T DE602006006827D1 (en) 2005-06-24 2006-06-02 PHARMACEUTICAL COMPOSITION WITH A 1- (3-CHLOROPHENYL) -3-ALKYLPIPERAZINE FOR THE TREATMENT OF APPETITOR DISORDERS
BRPI0611719-8A BRPI0611719A2 (en) 2005-06-24 2006-06-02 pharmaceutical use of a 1- (3-chlorophenyl) -3-alkylpiperazine, and, pharmaceutical composition
EA200800125A EA012443B1 (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating appetite disorder
DK06754160T DK1893208T3 (en) 2005-06-24 2006-06-02 Pharmaceutical composition with a 1- (3-chlorophenyl) -3-alkylpiperazine for the treatment of appetite disorders
AU2006261296A AU2006261296B9 (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
PL06754160T PL1893208T3 (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
CN2006800148322A CN101171011B (en) 2005-06-24 2006-06-02 Pharmaceutical compositions containing 1-(3-chlorophenyl)-3-alkylpiperazines for the treatment of appetite disorders
MX2007014396A MX2007014396A (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3- alkylpiperazine for treating apetite disorder.
JP2008517359A JP5142991B2 (en) 2005-06-24 2006-06-02 Pharmaceutical composition for treating appetite disorders comprising 1- (3-chlorophenyl) -3-alkylpiperazine
HK08104469.6A HK1111080B (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
KR1020077030116A KR101324689B1 (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
AT06754160T ATE431146T1 (en) 2005-06-24 2006-06-02 PHARMACEUTICAL COMPOSITION CONTAINING A 1-(3-CHLORPHENYL)-3-ALKYLPIPERAZINE FOR THE TREATMENT OF APPETITE DISORDERS
IL186334A IL186334A (en) 2005-06-24 2007-10-07 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating appetite disorder

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2005A001193 2005-06-24
IT001193A ITMI20051193A1 (en) 2005-06-24 2005-06-24 PHARMACEUTICAL USE OF A 1-3-CHLOROFENYL-3-ALCHILPIPERAZINE

Publications (1)

Publication Number Publication Date
WO2006136284A1 true WO2006136284A1 (en) 2006-12-28

Family

ID=35198058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005390 Ceased WO2006136284A1 (en) 2005-06-24 2006-06-02 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder

Country Status (23)

Country Link
US (1) US7879836B2 (en)
EP (1) EP1893208B1 (en)
JP (1) JP5142991B2 (en)
KR (1) KR101324689B1 (en)
CN (1) CN101171011B (en)
AR (1) AR054491A1 (en)
AT (1) ATE431146T1 (en)
AU (1) AU2006261296B9 (en)
BR (1) BRPI0611719A2 (en)
CA (1) CA2604584C (en)
DE (1) DE602006006827D1 (en)
DK (1) DK1893208T3 (en)
EA (1) EA012443B1 (en)
ES (1) ES2325744T3 (en)
GE (1) GEP20094787B (en)
IL (1) IL186334A (en)
IT (1) ITMI20051193A1 (en)
MX (1) MX2007014396A (en)
PL (1) PL1893208T3 (en)
PT (1) PT1893208E (en)
SI (1) SI1893208T1 (en)
UA (1) UA89236C2 (en)
WO (1) WO2006136284A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3253989A (en) * 1963-02-11 1966-05-31 American Cyanamid Co Process for producing anorexia
US3637705A (en) * 1968-10-01 1972-01-25 Abbott Lab N-3 4-dihalo phenyl piperazines
US3929792A (en) * 1972-09-29 1975-12-30 D Emile Bouchara Phenylpiperazine derivatives, process for their preparation and applications thereof
WO1993014091A1 (en) * 1992-01-17 1993-07-22 Istituto Ricerca Francesco Angelini S.P.A. Alkyl derivatives of trazodone with cns activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (en) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
EP1644347A1 (en) * 2003-06-20 2006-04-12 Arena Pharmaceuticals, Inc. N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3253989A (en) * 1963-02-11 1966-05-31 American Cyanamid Co Process for producing anorexia
US3637705A (en) * 1968-10-01 1972-01-25 Abbott Lab N-3 4-dihalo phenyl piperazines
US3929792A (en) * 1972-09-29 1975-12-30 D Emile Bouchara Phenylpiperazine derivatives, process for their preparation and applications thereof
WO1993014091A1 (en) * 1992-01-17 1993-07-22 Istituto Ricerca Francesco Angelini S.P.A. Alkyl derivatives of trazodone with cns activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GIANNANGELI M ET AL: "Effect of Mocifications of the Alkylpiperazine Moiety of Trazodone on 5HT2A and alpha-1 Receptor Binding Affinity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 3, 1999, pages 336 - 345, XP002142123, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
DK1893208T3 (en) 2009-08-31
AR054491A1 (en) 2007-06-27
CN101171011A (en) 2008-04-30
AU2006261296B9 (en) 2011-01-20
US20090054461A1 (en) 2009-02-26
KR20080026115A (en) 2008-03-24
ES2325744T3 (en) 2009-09-15
PT1893208E (en) 2009-06-26
CA2604584A1 (en) 2006-12-28
MX2007014396A (en) 2008-02-12
DE602006006827D1 (en) 2009-06-25
KR101324689B1 (en) 2013-11-04
PL1893208T3 (en) 2009-10-30
SI1893208T1 (en) 2009-10-31
IL186334A0 (en) 2008-08-07
GEP20094787B (en) 2009-09-25
JP2008546725A (en) 2008-12-25
EP1893208A1 (en) 2008-03-05
ITMI20051193A1 (en) 2006-12-25
AU2006261296A1 (en) 2006-12-28
EP1893208B1 (en) 2009-05-13
UA89236C2 (en) 2010-01-11
CA2604584C (en) 2013-07-16
IL186334A (en) 2011-02-28
AU2006261296B2 (en) 2010-12-16
ATE431146T1 (en) 2009-05-15
US7879836B2 (en) 2011-02-01
EA012443B1 (en) 2009-10-30
JP5142991B2 (en) 2013-02-13
CN101171011B (en) 2011-04-13
HK1111080A1 (en) 2008-08-01
EA200800125A1 (en) 2008-04-28
BRPI0611719A2 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
EP2275108A1 (en) Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
JP4415075B2 (en) Copper opiate agonists for inflammatory bowel disease
JP2025027020A (en) Combination for lowering serum phosphate in a patient - Patent application
EP0808166A1 (en) Medicament intended to the treatment of obsessive compulsive troubles, sleep apnoea, sexual dysfunctions, emesa and transport sickness
NZ543109A (en) Method of improved diuresis in individuals with impaired renal function
CN101715448B (en) Therapeutic uses of imidazol-5-carboxylic acid derivatives
EA015483B1 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
EA007952B1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
CA2604584C (en) Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
WO2007058335A1 (en) Use of tak-475 together with ezetimibe for treating hyperlipidemia
HK1111080B (en) Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
AU2008257319B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
CN102196809B (en) Agent for treatment of diabetic nephropathy
JP3881061B2 (en) Kidney disease prevention and treatment
WO1994016694A1 (en) Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
WO2005082351A1 (en) Therapeutic agent for neurodegenerative disorder
WO1997007806A1 (en) Preventive or remedy for kidney diseases
JPH1160483A (en) Tnf production inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006261296

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 186334

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2604584

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2006261296

Country of ref document: AU

Date of ref document: 20060602

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006261296

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680014832.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006754160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014396

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020077030116

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008517359

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 10483

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 200800125

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 409/CHENP/2008

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2006754160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11910559

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0611719

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071207